Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
  • TickerGNFT
  • ISINFR0004163111
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Anis Zgaya ...
  • Christophe Chaput
  • Hana Maalej
  • Khaled Ben Amor
  • Martial Descoutures
  • Oussema Denguir

ODDO BHF Small & MIDCAP MORNING NEWS - 11/26/2019

Amid spiralling labour and energy costs (additional € 30m in 2019), Elis should be able to shield its EBITDA margin (31.5% on our estimates), reflecting a capacity to get price increases accepted without hurting volumes (organic growth estimated at +3.3%). In 2020, FCF generation (€ 268m vs € 165m in 2019) is set to benefit from a reduction in the capex budget (18% of revenue vs. 20% in 2019) and recent efforts to optimise the debt structure (average cost 1.5% vs. 1.8%). We are mainta...

Martial Descoutures ...
  • Oussema Denguir

Genfit : Penalised by Cymabay once again

>Another read-across with Cymabay - After the disappointing results from phase IIb testing published in June, Cymabay (-76% yesterday) has announced a halt to the clinical development of its candidate medicine seladelpar. The decision to interrupt this development is based on the first histological results observed during the phase IIb trial in NASH. Histological evaluations revealed “atypical histological” results, including histology described as interface hepa...

Jean-Jacques Le Fur

GENFIT: Another thunderstorm coming from Cimabay | BUY | EUR65(+366%)

GENFIT - BUY | EUR65(+366%) Another thunderstorm coming from Cimabay Cimabay halts the development of seladelpar No such signal seen

Anis Zgaya ...
  • Christophe Chaput
  • Hana Maalej
  • Khaled Ben Amor
  • Martial Descoutures
  • Oussema Denguir

ODDO BHF Small & MIDCAP MORNING NEWS - 26/11/2019

Dans un contexte d’inflation des charges salariales et énergétiques (surcoût 30 M€ en 2019), le groupe devrait réussir à maintenir sa marge d’EBITDA (31.5% selon nous). Ceci témoigne de la capacité d’Elis à faire accepter ses hausses de prix sans pénaliser les volumes (croissance organique +3.3%e). En 2020, la génération de FCF (268 M€ vs 165 M€ en 2019) bénéficiera, de surcroît, de la réduction de l’enveloppe de Capex (18% du CA vs 20% en 2019) et des récentes optimisations de la str...

Martial Descoutures ...
  • Oussema Denguir

Genfit : Penalised by Cymabay once again

>Another read-across with Cymabay - After the disappointing results from phase IIb testing published in June, Cymabay (-76% yesterday) has announced a halt to the clinical development of its candidate medicine seladelpar. The decision to interrupt this development is based on the first histological results observed during the phase IIb trial in NASH. Histological evaluations revealed “atypical histological” results, including histology described as interface hepa...

Jean-Jacques Le Fur

GENFIT: Another thunderstorm coming from Cimabay | BUY | EUR65(+366%)

GENFIT - BUY | EUR65(+366%) Another thunderstorm coming from Cimabay Cimabay halts the development of seladelpar No such signal seen

Martial Descoutures ...
  • Oussema Denguir

Genfit : De nouveau pénalisé par Cymabay

>Un nouveau read across avec Cymabay - Après des premiers résultats de phase 2b décevants publiés en juin dernier, Cymabay (-76% hier) annonçait hier arrêter le développement clinique de son candidat médicament seladelpar. Cette décision s'appuie sur les premiers résultats histologiques observés lors de l'étude de phase 2b dans la NASH. Cette évaluation a révélé des résultats « histologiques atypiques », y compris une histologie caractérisée comme une hépatite d'...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior